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Abstract 
The case to be explored is a 22 year old female who presented in a psychotic state after stopping 
her medication to treat symptoms of mania associated with bipolar disorder. Methamphetamine 
was also being used and contributed to the psychotic state. The patient was found to be pregnant 
upon assessment. Treating a psychiatric disorder during pregnancy can be difficult, as many 
antipsychotic and mood stabilizing medications are not well studied during pregnancy and some 
are known teratogens. The Psychiatric Mental Health Nurse Practitioner (PMHNP) is challenged 
with treating the patient and her developing fetus, choosing a medication that will cause the least 
amount of risk to the patient, and also cause the least chance of fetal anomalies related to 
medication exposure in utero.  
Keywords: antipsychotics, mood stabilizing, pregnancy, teratogens, anomalies, fetus, 
bipolar, psychotic, mania, medication, Psychiatric Mental Health Nurse Practitioner, PMHNP 
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Use of Antipsychotic and Mood Stabilizing Medication in Pregnancy 
Background 
 Over half of all pregnancies that occur are unplanned. Psychiatric disorders, such as 
bipolar disorder can cause patients to engage in risky sexual behaviors. The use of illicit drugs 
can also increase the chance that a patient will engage in risky behaviors that they may not have 
previously when sober. All of these situations can cause providers to be faced with a challenging 
case of prescribing antipsychotics and mood stabilizers during pregnancy, whether it be a 
planned or unplanned pregnancy.  
The provider must be confident in treating a psychiatric patient and have education 
regarding what medications would be the safest for the expectant mother and the developing 
fetus. A patient encountered during a clinical experience with a history of bipolar disorder and 
methamphetamine use was found to be pregnant. The patient was unaware of the pregnancy. The 
patient was not taking her prescribed psychiatric medication and was in a psychotic state where 
she was having command hallucinations telling her to harm herself and others. This led to the 
patient needing medication to keep both her and her fetus safe.  
 Many medications have been identified as being unsafe to use during pregnancy because 
of the risk of harm and side effects to the fetus. Previously, medications were given a letter grade 
to identify how safe or risky a medication was to use during pregnancy based on risk to the fetus. 
As of June 30, 2015, the Federal Drug Administration (FDA) has decided to phase out and 
remove the letter grading for prescription medications (Stahl, 2017). Prescription drugs will now 
be labeled according to the Pregnancy and Lactation Labeling Rule (PLLR), which has the goal 
of creating safer and more effective use of all prescription medications in women who are at 
child bearing age, lactating, or are pregnant (U.S. Food and Drug Administration, 2018). 
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 When prescribing medication to pregnant, lactating, and even women of child bearing 
age, the benefits of using the medication must outweigh the risks of not using the medication 
during this time. There are ethical considerations when using a pregnant woman in a controlled 
study regarding medication, so there are very limited studies regarding various medications in 
pregnancy. Data obtained in the literature review often came from various medication registries 
that were created for providers who could report any defects or anomalies from medications used 
during pregnancy. This information then educates providers on choosing medications when 
benefit of using the medication outweighs the risk of no medication used.  
Patient Case Report 
 *Note that some information is intentionally left blank to respect patient privacy. 
Identifying Information: S.B. was a 22-year-old Caucasian female who was single and lived in 
a small rural community with her dad and step-mother infrequently. Many times she was 
homeless. S.B. was brought to clinic with local law enforcement and Emergency Outpatient 
Department (EOD) Registered Nurse (RN).  
Chief Complaint: “Someone is telling me to cut your throat. I’m going to cut my throat.”  
History of Present Illness: S.B. was initially diagnosed with Bipolar I Disorder when she was 18-
years-old. She has been tried on several medications since the time of diagnosis. S.B. has been 
unreliable with taking her medication and completing follow-up appointments with the mental 
health care provider. Early last year, S.B. was brought to the local EOD after displaying erratic 
and psychotic behaviors. In the EOD, S.B. requested multiple times to leave. She was placed on 
an emergency hold for the safety others, as well as herself. In the EOD she was given a ‘B-52’ 
intramuscular injection of Haloperidol (Haldol) 2 mg, Diphenhydramine (Benadryl) 50 mg, and 
Lorazepam (Ativan) 2 mg. The medication concoction did calm her down that night in the EOD 
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and she was able to sleep for a few hours. Blood was drawn and a urine specimen was obtained 
for testing and it was discovered that she was positive for methamphetamines and 
tetrahydrocannabinol (THC) at the time. Urinalysis also confirmed a positive pregnancy test; this 
information was withheld from the patient at the time until she could be assessed by the Psychiatric 
Mental Health Nurse Practitioner (PMHNP) in the clinic the following Monday morning. Upon an 
escort from the EOD to the clinic with law enforcement and EOD staff nurse, S.B. was assessed 
by a PMHNP for emergency hold review and medication recommendations.  
Past Psychiatric History: S.B. was hospitalized for inpatient care for one month following 
overdose on quetiapine (Seroquel) last spring. She had no previous history of self-injury or 
homicidal thoughts. Previous medication trials include Aripiprazole (Abilify), quetiapine 
(Seroquel), escitalopram (Lexapro), bupropion (Wellbutrin), olanzapine (Zyprexa), clonazepam 
(Klonopin). S.B. was started on medication to target depression when she was 16 years old. She 
complained of side effects including weight gain and was not compliant with taking medications 
for long periods of time. The effectiveness of the medications were questionable, as S.B. was 
using methamphetamines since 18 years old, which would cause her to hallucinate. S.B. was 
vague in regards to a timeline of her past psychiatric medication history.  
Substance Use and Addiction: History of methamphetamine misuse since 18 years old and 
marijuana misuse since 16 years old. No history of chemical dependency treatment. No history 
of withdrawal symptoms.  
Family Psychiatric/Chemical Dependency History: Biological mom diagnosed with Bipolar I 
Disorder and substance abuse. Biological dad with a history of substance abuse.  
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Social History: S.B. was born and raised in a small rural community. Parents were divorced and 
she had been living with her dad and step-mom infrequently. S.B. graduated from high school 
and did not attend college. She had no issues with meeting developmental milestones. No history 
of abuse or neglect. Patient is currently homeless when she was not staying with her boyfriend or 
parents. She has had periods of having her own apartment and paying rent with money she had 
made selling tickets and working at a concession stand at a recreation area. S.B. is currently 
employed at the recreation area and has held this part-time job for approximately the last year. 
She relies on her dad and step-mother for financial support. 
Legal History: She has multiple traffic violations with a current open case with charges pending 
that do not allow her to be hospitalized for psychiatric care across state lines. Legal charges 
include shoplifting, driving under suspension, and speeding. No history of violent or assault 
charges.  
Current Medications: She is not currently compliant with medication and had last been 
prescribed olanzapine 10 mg daily by mouth and quetiapine 200 mg daily by mouth. It was 
unknown when she last took this medications was 
Current Labs/Studies: Positive for amphetamines and THC. Positive urine pregnancy test.  
Mental Status Exam: Upon assessment by the PMHNP, S.B. was wearing a Post-It note over an 
eye and a surgical mask over her mouth; appearance is disheveled. She is fidgety and hyperactive 
during assessment and does not make eye contact during much of the assessment. She was dressed 
in hospital scrubs. S.B. was oriented to self only. S.B.’s mood was labile. Attention and 
concentration were scattered and variable. Speech was pressured upon assessment. S.B. presented 
with paranoid delusions and auditory hallucinations of voices telling her to kill herself by cutting 
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her throat open. She was homicidal and had auditory hallucinations of voices telling her to cut the 
throats of others around her to kill them. S.B.’s thoughts were racing and disorganized; 
associations were loose, which made it difficult to gather full assessment information. S.B. 
reported that she had stopped taking her medication “months ago”. Judgment and insight were 
poor. S.B. was tearful after being told that she was pregnant.  
Impression: S.B. was not stable at this time. She was psychotic and under the influence of 
amphetamines. She did not know that she was pregnant and cried when she was told the 
information. It was determined she was a danger to herself and others and required inpatient 
psychiatric care.  
Diagnosis: (F31.2) Bipolar I Disorder, with psychotic features. (F40.10) Generalized Anxiety 
Disorder. (12.10) Cannabis Use Disorder, mild. (15.20) Stimulant Use Disorder, severe, 
amphetamine-type stimulant.  
Treatment Plan: S.B. continued under the emergency hold and was then transferred to a 
Minnesota inpatient psychiatric facility under commitment. After review of the most appropriate 
medication for the treatment of target symptoms present with current pregnancy status, it was 
determined to treat S.B. with olanzapine 10 mg by mouth daily. This was prescribed for 
treatment of psychotic symptoms. Lithium 300 mg by mouth BID was prescribed to treat her 
symptoms of Bipolar I Disorder. Medication risks, benefits, and side effects were reviewed with 
the patient. There was a plan to check her Lithium level in one week. Prenatal assessment for 
care of the fetus was provided in the EOD prior to transfer to psychiatric facility. S.B. will follow 
up with PMHNP in the outpatient clinic after discharge from the inpatient psychiatric hospital.  
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Literature Review 
Mental Illness and Pregnancy 
 Studies have shown that 8% of women in the United States from ages 15 to 54 years old 
have a severe mental illness, including, but not limited to bipolar disorder (Allison, 2004). If a 
woman with a mental illness currently is stabilized on psychotropic medication and she discovers 
that she is pregnant, stopping the psychotropic medication puts her and the fetus at immediate and 
long-term risk of re-emergence of psychiatric symptoms. This can include, though are not limited 
to having hallucinations that command the woman harm herself and/or the fetus, harm others, 
engaging in risky behaviors, and engaging in drug or alcohol use. Depending on what psychiatric 
medication is currently being prescribed, continuing the medication could put the fetus at the risk. 
It is essential for the provider to determine what medication is appropriate for treating the woman’s 
psychiatric disorder, while determining which medication is associated with the least risk of fetal 
anomalies.  
With data that shows that more than half of all pregnancies are unplanned, it is important 
that the providers educate women about the risks of taking psychotropic medications during 
pregnancy. Providing medication education when first prescribed to the child-bearing aged woman 
is best practice (Galbally, Snellen, Walker, & Permezel, 2010; Howland, 2009; Wichman, 2016). 
Women in the window of reproductive ages who are educated about the risks of medications during 
pregnancy are better able to make decisions regarding birth control or switching to a different 
medication with decreased risks of causing fetal anomalies. 
Severe mental illness, such as bipolar often require the use of more than one psychotropic 
medication, including mood stabilizers and antipsychotic medication (Kimmel, et al., 2016). This 
can make the prescribing of medication during pregnancy more complicated when deciding on the 
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safest medication to utilize based on side effect profile and efficacy. Women who have been tried, 
and possibly have failed on multiple mood stabilizers or antipsychotics may have a difficult time 
deciding on what will be best for their mental health and the health of their unborn child. 
Empowering women to make the best and most appropriate choice in this situation is essential. A 
multi-disciplinary approach can be beneficial for women during this time. Psychiatric providers, 
PMHNPs, and social workers can work together to help women with their ambivalence and 
specific concerns regarding the use of medication during pregnancy (Bentley, Price, & Cummings, 
2014).  
Determining the use of Psychotropic Medication in Pregnancy 
 Women taking psychotropic medications to prevent the relapse of symptoms of a mental 
illness must make the decision to continue these medications into pregnancy based on their own 
physical and mental health, as well as the health of their offspring. There can often be 
contraindications between the two decisions (Allison, 2004). Safety of the mother and the 
developing fetus must be taken into account by all providers who are assisting in care. Care 
requires a multidisciplinary approach, including the mental health provider, 
obstetrical/gynecological provider, and community support services (Galbally, Snellen, Walker, 
& Permezel, 2010).  Toh, et al., (2013) have identified that it is beneficial to both the expectant 
mother and the developing fetus to treat the mother’s psychiatric symptoms during pregnancy. 
Treatment during pregnancy involves the psychiatric illness, risks and benefits of the psychiatric 
medication to be used, and the risks or benefits of leaving the psychiatric illness untreated during 
the pregnancy.  
 
 
ANTIPSYCHOTIC/MOOD STABILIZER MEDICATION IN PREGNANCY 10 
 
Fetal Anomalies with Psychotropic Medication Use 
Whatever medication is chosen to use or continue during pregnancy to prevent relapse of 
psychiatric symptoms, the lowest dose that is possible to relieve symptoms for the shortest period 
of time possible should be used (Allison, 2004; Howland, 2009). Smaller doses for shorter periods 
of time can decrease the risk of malformation of the developing fetus. Allison (2004) has identified 
that the incidence of anomalies caused by psychotropic medications in general is low, at 2-4%, 
whereas the baseline of anomalies in the United States, regardless of medication use during 
pregnancy is 2.5%. Technically, there are no medications that do not cross the placenta and all 
medications carry the risk of teratogenic effects (Allison, 2004). Behavioral and physical 
anomalies may be present at birth, but some have been found to manifest later in life (Allison, 
2004).  
The fetus is exposed to a higher level of the psychotropic medication in utero due to the 
medication passing through the placenta. This occurs through decreased protein levels, which 
allows more of the drug to be unbound and enter the fetus. The fetus has a decreased metabolism, 
immature nervous system, and immature liver enzymes, all of which can be affected by the passage 
of medication to the fetus (Kulkarni, et al., 2008). With immature development of bodily systems, 
the fetus is at risk of greater exposure to the psychotropic medication, which can potentiate 
negative side effects such as future anomalies.  
Mood Stabilizer use in Pregnancy 
 Antiepileptic medications such as Depakote and Tegretol have been used in psychiatric 
patients as a mood stabilizing medication. There has been research done to support these 
medications cause cause neural tube deficits, specifically spina bifida, when taken during 
pregnancy. The risk of this defect is especially high during the first trimester when organs and 
ANTIPSYCHOTIC/MOOD STABILIZER MEDICATION IN PREGNANCY 11 
 
limbs are developing. Both of these medications should be avoided in pregnant women requiring 
the medication for mood stabilization (Allison, 2004; Galbally, Snellen, Walker, & Permezel, 
2010; Howland, 2009; Wichman, 2016). Depakote has the highest instance of consistently 
resulting in an anomaly, at 8.7% (Galbally, Snellen, Walker, & Permezel, 2010; Howland, 2009) 
and Lamictal has been found to have the lowest risk of anomalies. Lamictal could be used if no 
other mood stabilizing medications can be used (Howland, 2009; Wichman, 2016).  
Lithium has been found to be the safest mood stabilizing medication to use during 
pregnancy. In studies done on the use of Lithium during pregnancy, there have been no behavioral 
anomalies present in later life (Allison, 2004; Stahl, 2017). There also have not been any 
differences in intelligence quotient (IQ) in children exposed in utero to Lithium to those who were 
not exposed to Lithium in utero (Wichman, 2016). Physical anomalies related to fetal Lithium 
exposure have been found to include Ebstein’s anomaly, neonatal hypothyroidism, goiter, 
nephrogenic diabetes insipidus, hypoglycemia, increased birth weight, polyhydramnios, and 
floppy baby syndrome (Allison, 2004; Galbally, Snellen, Walker, & Permezel, 2010; Stahl, 2017; 
Ward & Zamorski, 2002; Wichman, 2016).  
Ebstein’s anomaly is the most frequent side effect related directly to intra-utero Lithium 
exposure. This risk of Ebstein’s anomaly is 400 times the normal rate in a fetus exposed to Lithium 
than one that is not, or 0.05 to 0.1% more likely (Allison, 2004; Galbally, Snellen, Walker, & 
Permezel, 2010). 1 to 2 infants out of every 1,000 with exposure to Lithium in utero compared to 
1 infant out of 20,000 without exposure to Lithium in utero developed Ebstein’s anomaly (Ward 
& Zamorski, 2002; Wichman, 2016).  
Ebstein’s anomaly is a heart defect where the right atrium is separated from the right 
ventricle by the tricuspid valve, which allows unoxygenated blood to flow into the body 
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(Cincinnati Children’s Hospital Medical Center, 2018). Ebstein’s anomaly can be surgically fixed 
following delivery and is not considered to be a long term defect (Cincinnati Children’s Hospital 
Medical Center, 2018; Wichman, 2016).  
To decrease the incidence of cardiac anomalies, Lithium should not be taken from days 18 
to 55 after conception (Allison, 2004). As previously identified, over half of pregnancies are 
unplanned, making this very difficult to determine (Galbally, Snellen, Walker, & Permezel, 2010; 
Howland, 2009; Wichman, 2009). Stopping the medication during this 37 day period increases the 
risk of a relapse of symptoms, thus exposing the fetus to indirect exposure to mental illness and 
dangerous activities, such as drug use, alcohol use, or self-injurious (Allison, 2004; Howland, 
2009). Women with bipolar who stop taking their mood stabilizing medication “are more than 
twice as likely to relapse in pregnancy (85.5% vs 37%) and are ill for fivefold longer during their 
pregnancy than those who continue their medications” to treat their mental illness (Galbally, 
Snellen, Walker, & Permezel, 2010, p. 100).  
For the reason that stopping the medication may not be beneficial, or is determined to cause 
the least amount of harm to the woman and fetus, fetal ultrasounds and echocardiography should 
be done at 16, 18, 20, and 22 weeks of pregnancy (Allison, 2004; Galbally, Snellen, Walker, & 
Permezel, 2010). Pregnancy causes many changes to the woman’s body, including fluid shifts, 
increased glomerular filtration rate, and increases in blood volume. All of these bodily changes 
may lead to sub-therapeutic Lithium levels, so it is important to monitor Lithium levels carefully 
during the entire pregnancy. At times, higher doses of Lithium may be needed (Allison, 2004; 
Galbally, Snellen, Walker, Permezel, 2010; Wichman, 2016).  
During the third trimester, gastric motility and emptying can decrease. The ability of 
Lithium’s capacity to bind can decrease. Also during the third trimester, fluid volume and hepatic 
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metabolism increases. Lithium level should be monitored monthly and then weekly at 36 weeks 
gestation to see if a dosage increase or decrease needs to be made based on the woman’s fluid 
levels (Galbally, Snellen, Walker, & Permezel, 2010). 
The most common fetal issue following Ebstein’s anomaly is floppy baby syndrome, which 
is hypotonia, or decreased muscle tone that is present immediately at birth (WebMD, 2015). To 
prevent floppy baby syndrome, the expectant mother should stop the Lithium 24-48 hours prior to 
delivery (Galbally, Snellen, Walker, & Permezel, 2010; Stahl, 2017). If the risk of stopping the 
Lithium prior to delivery outweighs the benefits, it is recommended that the Lithium dosage then 
be decreased to the dose that was used prior to pregnancy, or decreased by two-thirds of the pre-
pregnancy dose (Wichman, 2016). It is important that the expectant woman be hydrated with 
intravenous fluids consistently during the time of delivery, as well as immediately after delivery 
(Wichman, 2016). If Lithium toxicity of the infant is suspected, cord blood should be tested to 
determine the Lithium level in the cord blood (Galbally, Snellen, Walker, & Permezel, 2010). The 
infant and the mother should be closely monitored following delivery regardless of what 
medication side effects were or were not present, as side effects and withdrawal symptoms can 
occur quickly.  
Antipsychotic use in Pregnancy 
There is conflicting information from studies regarding the safety of antipsychotics use 
during pregnancy. Some studies have found that there is an increase in congenital malformation, 
but others have not found a link between antipsychotic use and fetal anomalies (Toh, et al., 2013). 
Up to date studies have identified there is an increased chance of an infant being stillborn, being 
larger or smaller for gestational age, or being born prematurely if exposed to antipsychotics in 
utero (Wisner, Jeong, & Chambers, 2016). Information that is available on the use of 
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antipsychotics during pregnancy is often limited to atypical antipsychotics (Margulis, Kang, & 
Hammond, 2014).  
While the incidence of fetal malformation related to antipsychotic use in pregnancy is not 
well studied, a recent study done on 1,341,715 pregnant women found that there was not an 
increased risk of a congenital anomalies, including cardiac malformation with the use of atypical 
antipsychotics. Only risperidone was found to have an increased risk of congenital fetal 
malformations (Huybrechts, et al., 2016; Wisner, Jeong, & Chambers, 2016). According to the 
study by (Wisner, Jeong, & Chambers, 2016), the increase in the fetal risk of anomalies with 
risperidone has been linked to the CYP 2D6 pathway for metabolism. Fetal risks associated with 
risperidone includes abnormal muscle movements and withdrawal following delivery (Stahl, 
2017). With this current data and information in mind, the use of aripiprazole, quetiapine, 
olanzapine, ziprasidone, or clozapine can be used when the small risk of an anomaly outweighs 
the risk of leaving a psychiatric disorder, such as bipolar, untreated during pregnancy (Huybrechts, 
et al., 2016; Wichman, 2016).  
Atypical antipsychotics are often times added to the medication regimen of someone 
presenting with bipolar, such as with the patient case example. There are few studies available on 
the use of antipsychotics during pregnancy and the risks of an anomaly. It has been found that 
atypical antipsychotics, such as olanzapine are much safer for the fetus than typical antipsychotics 
during pregnancy (Allison, 2004; Galbally, Snellen, Walker, & Permezel, 2010). 
 There is the risk of weight gain when taking an antipsychotic. Weight gain can lead to 
further complications during pregnancy including diabetes, high blood pressure, and high 
cholesterol (Kulkarni, et al., 2008; Stahl, 2013, 2017). Pregnant women taking atypical 
antipsychotics, such as olanzapine have a chance of delivering a greater weight baby and 
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developing gestational diabetes (Galbally, Snellen, Walker, & Permezel, 2010; Gentile, 2008; 
Kulkarni, et al., 2008). Laboratory tests during pregnancy should include a glucose tolerance test 
between 14-16 weeks gestation and a glucose challenge test at gestation week 28 to identify a high 
risk illness during pregnancy (Galbally, Snellen, Walker, & Permezel, 2010). Additional 
monitoring of the expecting mother should include blood pressure, weight, body mass index, and 
lipids to identify any high illnesses early during the pregnancy (Wichman, 2016).  
Upon delivery, there is a small chance that the infant will have transient extra-pyramidal 
effects and sedation when exposed to antipsychotics (Galbally, Snellen, Walker, & Permezel, 
2010; Ward & Zamorski, 2002). These transient symptoms of extra-pyramidal effects will 
typically cease after the infant reaches age 10 months (Kulkarni, et al., 2008). There have been 
some identified cognitive, motor, social, and emotional delays in infants exposed to antipsychotics. 
These delays have been transient and typically disappear by age 12 months of age (Wichman, 
2016).  
S.B’s Pregnancy and Medications 
S.B., a 22 year old female is at the age where the chance of planned or unplanned pregnancy 
is a possibility, regardless of mental health status. When a diagnosis of bipolar is added into the 
patient’s psychiatric background, there is the risk of increased sexual promiscuity during a manic 
episode (American Psychiatric Association, 2013). This further increases the risk for an 
unintended pregnancy. 
Psychiatric symptoms take a toll on the woman’s emotions, ability to function in daily 
activities, ability to achieve appropriate prenatal care, and their ability to differentiate between 
appropriate behaviors and those that are considered dangerous (Ward & Zamorski, 2002). When 
bipolar disorder is left untreated and without mood stabilizers or antipsychotics during pregnancy, 
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a woman with bipolar disorder has a greater chance of emerging symptoms that interfere with 
appropriate prenatal care, use of harmful substances, premature delivery, decreased or increased 
infant birth weight, infant growth retardation, antepartum hemorrhage, fetal distress, cardiac 
anomalies, eclampsia, and stillbirth risk (Allison, 2004; Dresner, Byatt, Gopalan, Miller, & 
Sachdeva, 2015; Galbally, Snellen, Walker, & Permezel, 2010; Gentile, 2010; Wichman, 2016). 
In order for a woman to achieve their maximum ability for self-care and care of their 
developing fetus, the PMHNP should ensure that the patient is being appropriately assessed for 
what services are needed during the pregnancy. Assessment includes obtaining information from 
previous psychiatric episodes and the severity of each, which psychiatric medications worked and 
how well the medication worked for their psychiatric illness (Ward & Zamorski, 2002). “The most 
important consideration is the patient’s past level of function when not taking medications” (Ward 
& Zamorski, 2002, p.632).  
Implications for Practice, Research, and Education 
 To better provide care for patients who are diagnosed with a psychiatric illness, it is 
important that PMHNPs are up to date on current research about various diagnoses, treatment 
options, and medications. Psychiatric patients are a unique group of patients, which can be 
further complicated when a woman with a psychiatric illness become pregnant. Women of child 
bearing age should be educated at each visit regarding pregnancy risks, birth control, and the 
risks that go along with psychiatric medications prescribed for their treatment. PMHNPs should 
ensure that the safest treatment option is used during a woman’s pregnancy. This includes a 
treatment option that decreases the risk of re-occurring psychiatric symptoms that place the 
mother and developing fetus at risk, as well as the benefit of using a known teratogenic 
medication outweighing the risk of. If the patient allows, the PMHNP should also be educating 
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the family members who are involved in the patient’s care. Education should be provided in 
writing and verbally. Each encounter should include documentation of understanding of the 
information provided for the treatment plan.  
 As previously discussed, it would be beneficial to have further data regarding the safety 
of mood stabilizing and antipsychotic medication use during pregnancy. To educate future and 
current PMHNPs and providers regarding the risks and benefits of psychiatric medication during 
pregnancy, the PMHNP could speak at conferences and participate in research. The PMHNP 
could gather data, perform studies, and complete literature reviews based on this important topic.  
 The PMHNP should keep in close contact with the patient’s obstetric/midwife provider. 
This ensures that information between the two disciplines is accurate and passed on in a timely 
fashion. Having other multi-disciplinary staff involved in this process would further benefit the 
woman and the fetus. Some pregnant women may experience a mental health crisis during their 
pregnancy and need inpatient hospitalization care. A psychiatrist could be consulted to provide 
further expertise and direction as to how treatment should be offered. If the woman is at serious 
risk of harming herself and/or the fetus, the PMHNP may need to collaborate with other 
disciplines to have the woman committed to an inpatient psychiatric facility for stabilization.  
PMHNPs should use the most up to date information when prescribing medications and 
any side effects or adverse outcomes should be reported. Up to date information can be obtained 
in reputable publishing materials, such as Stahl’s Essential Psychopharmacology Prescriber’s 
Guide or UpToDate. UpToDate is a database that includes evidence based practice treatment 
guidelines for treatment of patients (UpToDate, Inc., 2018).  
PMHNPs are faced with many difficult decisions in how to provide the best treatment for 
their patients. Patients should be included on the discussion of treatment options, evidence based 
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practice should be reviewed, and consults to other disciplines should be made when appropriate. 
It is important to keep in mind that the benefit of treatment or lack of treatment should always 
outweigh risks involved with a treatment plan or the lack of treatment provided to a patient.  
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